Low-Dose Oral Corticosteroids Offer More Promising Outcomes for MG Patients than Higher Doses

Researchers found that a low-dose regimen of oral corticosteroids is better than high- or intermediate-dose regimens in maintaining treatment goals for patients with myasthenia gravis (MG). The study “Oral corticosteroid dosing regimen and long-term prognosis in generalised myasthenia gravis: a multicentre cross-sectional study in Japan” was published in the…

Study Explains Why MuSK MG Patients Relapse After Rituxan Therapy

A recent study by researchers from Yale University furthers understanding about why certain myasthenia gravis (MG) patients who were treated with Rituxan (rituximab) may relapse. Findings of the study, “Autoantibody-producing plasmablasts after B cell depletion identified in muscle-specific kinase myasthenia gravis,” were published at The Journal of Clinical…

2021 Myasthenia Gravis Survey Results

BioNews Survey Infographic

Myasthenia Gravis News conducted a survey from Feb. 11-March 28 to gain greater insight into the characteristics of the MG community and disease management. Results of the survey have now been published. Click on the image to view the infographic, and click here to read the story.